Prostate Cancer Clinical Trials

Official title: Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate Cancer · McGill University Health Centre/Research Institute of the McGill University Health Centre

Testing Lupron Depot for prostate cancer

Explore this study →

Sites in Halifax, Montreal and 1 more city

Official title: Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Prostate Cancer · Ottawa Hospital Research Institute

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for prostate cancer.

Testing Apple Cider Vinegar for prostate cancer

Explore this study →

One site, in London

RecruitingEARLY PHASE1

Official title: Akkermansia Muciniphilia and Metabolic Side Effects of ADT

Prostate Cancer · Western University

Testing AAA617 for prostate cancer

Explore this study →

One site, in Montreal

RecruitingPHASE4

Official title: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer · Novartis Pharmaceuticals

Testing AAA617 with piflufolastat for oligometastatic prostate cancer (OMPC)

Explore this study →

Sites in Montreal, Calgary and 5 more cities

Official title: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC) · Novartis Pharmaceuticals

Testing BMS-986460 for metastatic castration-resistant prostate cancer

Explore this study →

Sites in Montreal and Toronto

Official title: A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer · Bristol-Myers Squibb

Comparing Opevesostat with Abiraterone acetate for prostate cancer metastatic

Explore this study →

Sites in Toronto, Edmonton and 5 more cities

Official title: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic · Merck Sharp & Dohme LLC

Comparing Opevesostat with Abiraterone acetate for metastatic castration-resistant prostate cancer (mcrpc)

Explore this study →

Sites in Abbotsford British Columbia, Edmonton and 5 more cities

Official title: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC) · Merck Sharp & Dohme LLC

Comparing 177Lu-TLX591 with Enzalutamide for metastatic castration-resistant prostate cancer

Explore this study →

Sites in Burnaby and Toronto

Official title: The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Metastatic Castration-resistant Prostate Cancer · Telix Pharmaceuticals (Innovations) Pty Limited

Comparing Abiraterone with Docetaxel for prostate cancer (adenocarcinoma)

Explore this study →

Sites in Montreal, Toronto and 15 more cities

Official title: Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Prostate Cancer (Adenocarcinoma) · Canadian Cancer Trials Group

Comparing ELIGARD with Recurrence-directed therapy for prostate adenocarcinoma

Explore this study →

Sites in Hamilton, Montreal and 1 more city

Official title: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Prostate Adenocarcinoma · Ontario Clinical Oncology Group (OCOG)

Testing 177Lu-PSMA-617 for metastatic castrate resistant prostate cancer (mcrpc)

Explore this study →

One site, in Québec

Official title: Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

Metastatic Castrate Resistant Prostate Cancer (mCRPC) · Jean-Mathieu Beauregard

Comparing Mevrometostat with Enzalutamide for metastatic castration sensitive prostate cancer (mcspc)

Explore this study →

Sites in Montreal, Calgary and 7 more cities

Official title: This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Metastatic Castration Sensitive Prostate Cancer (mCSPC) · Pfizer

Comparing 4 approaches for prostate cancer

Explore this study →

Sites in Québec and Toronto

Official title: A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

Prostate Cancer · AstraZeneca

Comparing Actinium (225Ac) zadavotide guraxetan with Cabazitaxel for metastatic castration-resistant prostate cancer

Explore this study →

Sites in Montreal, Toronto and 3 more cities

Official title: AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Metastatic Castration-resistant Prostate Cancer · AstraZeneca

Testing Verteporfin with SpectraCure P18 System for recurrent prostate cancer

Explore this study →

One site, in Toronto

Official title: Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

Recurrent Prostate Cancer · SpectraCure AB

Comparing 8 approaches for prostate cancer

Explore this study →

Sites in London, Ottawa and 2 more cities

Official title: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Prostate Cancer · University of British Columbia

Comparing 3 approaches for metastatic prostate cancer

Explore this study →

2 sites in Toronto

Official title: Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Metastatic Prostate Cancer · University Health Network, Toronto

Testing 18F-PSMA-1007 for prostate cancer

Explore this study →

One site, in Edmonton

Official title: 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

Prostate Cancer · University of Alberta

Comparing 6 approaches for advanced metastatic castration-resistant prostate cancer

Explore this study →

Sites in Montreal, Edmonton and 4 more cities

Official title: First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Advanced Metastatic Castration-resistant Prostate Cancer · Bayer

Comparing Radiation with Radiation SBRT only for prostate cancer

Explore this study →

Sites in Montreal, Toronto and 7 more cities

Official title: Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Prostate Cancer · Canadian Cancer Trials Group

Comparing Docetaxel with Carboplatin for metastatic castration-resistant prostate cancer

Explore this study →

Sites in Montreal, Toronto and 10 more cities

Official title: Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Metastatic Castration-resistant Prostate Cancer · Canadian Cancer Trials Group

Comparing PF-06821497 with Enzalutamide for metastatic castration-resistant prostate cancer

Explore this study →

Sites in Calgary, Chicoutimi and 4 more cities

Official title: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-Resistant Prostate Cancer · Pfizer

Testing Semaglutide Pen Injector for prostate cancer

Explore this study →

One site, in Hamilton

RecruitingPHASE4

Official title: Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Prostate Cancer · Hamilton Health Sciences Corporation

Testing GSK5458514 for prostate neoplasms

Explore this study →

2 sites in Montreal

Official title: A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Neoplasms, Prostate · GlaxoSmithKline

Comparing 5 approaches for metastatic hormone-sensitive prostate cancer (mhspc)

Explore this study →

One site, in Montreal

Official title: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · Novartis Pharmaceuticals

Comparing 10 approaches for progressive metastatic castrate resistant prostate cancer

Explore this study →

One site, in Halifax

Official title: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer · Novartis Pharmaceuticals

Comparing Xaluritamig with Docetaxel for metastatic castration-resistant prostate cancer

Explore this study →

Sites in Montreal and Sherbrooke

Official title: A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer · Amgen

Comparing Inavolisib with Abiraterone for metastatic castration-resistant prostate cancer

Explore this study →

Sites in Montreal and Toronto